MedTrace Logo

A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

NCT02838264 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-05-15

No results posted yet for this study

Summary

The purpose of this study is to estimate the effect of itraconazole on the single dose pharmacokinetics of PF-06463922 in healthy volunteers in the fasted state.

Conditions

  • Healthy

Interventions

DRUG

PF-06463922

Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2

DRUG

PF-06463922

Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2

DRUG

PF-06463922

Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2

DRUG

PF-06463922

Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2

DRUG

Itraconazole

200 mg oral dose of itraconazole on Days 1 to 11 during Period 2

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-16
Primary Completion
2017-03-31
Completion
2017-05-03

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02838264 on ClinicalTrials.gov